A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

[1] Vermorken JB(2008)Platinum based chemotherapy plus cetuximab in head and neck cancer N Eng J Med 359 1116-1127

[2] Mesia R(2013)Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Lancet Oncol 14 697-710

[3] Rivera F(2005)A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy Clin Oncol (R Coll Radiol) 17 418-424

[4] Vermorken JB(2009)Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck J Clin Oncol 27 1864-1871

[5] Stöhlmacher-Williams J(2011)Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial Lancet Oncol 12 333-343

[6] Davidenko I(2008)Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies Cancer 112 2710-2719

[7] León X(2014)AXL mediates resistance to cetuximab therapy Cancer Res 74 5152-5164

[8] Hitt R(2011)Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab–docetaxel treatment Clin Cancer Res 17 5197-5204

[9] Constenla M(2008)Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Oncogene 27 3944-3956

[10] Stewart JS(2010)Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res 70 588-597

[1] Vermorken JB(2008)Platinum based chemotherapy plus cetuximab in head and neck cancer N Eng J Med 359 1116-1127

[2] Mesia R(2013)Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Lancet Oncol 14 697-710

[3] Rivera F(2005)A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy Clin Oncol (R Coll Radiol) 17 418-424

[4] Vermorken JB(2009)Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck J Clin Oncol 27 1864-1871

[5] Stöhlmacher-Williams J(2011)Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial Lancet Oncol 12 333-343

[6] Davidenko I(2008)Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies Cancer 112 2710-2719

[7] León X(2014)AXL mediates resistance to cetuximab therapy Cancer Res 74 5152-5164

[8] Hitt R(2011)Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab–docetaxel treatment Clin Cancer Res 17 5197-5204

[9] Constenla M(2008)Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Oncogene 27 3944-3956

[10] Stewart JS(2010)Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res 70 588-597